• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Hum Vaccin Immunother . Three seasons of enhanced safety surveillance of a cell culture-based quadrivalent influenza vaccine

tetano

Editor, Senior Moderator
Hum Vaccin Immunother


. 2023 Aug;19(2):2261689.
doi: 10.1080/21645515.2023.2261689. Epub 2023 Oct 3. Three seasons of enhanced safety surveillance of a cell culture-based quadrivalent influenza vaccine

Alexander Domnich[SUP] 1 [/SUP], Daniela Amicizia[SUP] 2 3 [/SUP], Piero Luigi Lai[SUP] 2 3 [/SUP], Matilde Ogliastro[SUP] 2 [/SUP], Maria Piedrahita-Tovar[SUP] 4 [/SUP], Andrea Orsi[SUP] 1 2 3 [/SUP], Giancarlo Icardi[SUP] 1 2 3 [/SUP], Donatella Panatto[SUP] 2 3 [/SUP]



Affiliations
Abstract

The objective of this paper is to summarize annual enhanced safety surveillance activity across three seasons (2019/20-2021/22) for cell culture-based quadrivalent influenza vaccine (QIVc; Flucelvax® Tetra) in all age groups. This activity was conducted in primary care setting in Genoa (Italy) during the seasons 2019/20, 2020/21 and 2021/22. All adverse events registered within the first seven days following immunization were analyzed by season, type, age group and seriousness. Over three seasons, 3,603 QIVc exposures were recorded within the enhanced passive safety surveillance activity. No safety signals were identified. The overall reporting rates of individual case safety reports for the seasons 2019/20, 2020/21 and 2021/22 were 1.75%, 0.48% and 0.40%, respectively. The average number of adverse events per individual case safety report was similar (range 3.3-3.8 adverse events per case report) across the three seasons. Most adverse events were reactogenic in nature. The rate of adverse events was similarly low in all age groups. Enhanced passive safety surveillance activity is a feasible approach for the post-marketing monitoring of seasonal influenza vaccines. Within its limitations, results of this study support the favorable safety profile of QIVc. These safety data could further bolster public trust in influenza vaccines with the goal to increase vaccination uptake in all target groups.

Keywords: Flucelvax® Tetra; Influenza; adverse event; cell-based influenza vaccine; enhanced safety surveillance; safety.

 
Back
Top Bottom